SHARE THIS POST

Feb 06, 2018 – GREENWOOD VILLAGE, CO, Feb. 06, 2018 (GLOBE NEWSWIRE) — Helix TCS, Inc. (OTCQB: HLIX), along with its investment partner Rose Capital, acquired all of the outstanding preferred stock of Bio-Tech Medical Software, Inc. (or BioTrackTHC).  This investment represents approximately 18.5% of BioTrackTHC’s outstanding capital stock, on an as-converted to common basis. In addition, Helix CEO Zac Venegas will join BioTrackTHC’s board.

“As we continue to execute our strategy of offering integrated operating services to the legal cannabis industry, we are excited to forge a stronger relationship with BioTrackTHC and work towards providing our clients with ways to operate with greater efficiency, security, compliance, and profitability,” stated Mr. Venegas.

Since its founding in 2015, Helix continues to grow in scale and scope in the legal cannabis industry, operating in the security, transportation and compliance sectors.  In 2016, it acquired Cannabase, the industry’s oldest electronic wholesale marketplace.

“We are impressed with BioTrackTHC’s growth and geographic footprint for seed-to-sale systems. Furthering our relationship with BioTrackTHC is an important step in our finding ways to support the technology and data capabilities of all of our business lines, including Cannabase,” stated Venegas.

About Helix TCS

Helix TCS, Inc. (OTCQB: HLIX) www.helixtcs.com is a premier provider of integrated operating environment solutions for the legal cannabis industry.  Helix provides a proprietary software suite and partnership platform to the legal cannabis industry, helping clients manage inventory and supply costs and bespoke monitoring and transport solutions.  Helix provides clients in the legal cannabis industry high standard security operations, including transportation, armed and unarmed guarding, training, investigation, and special services.

About Rose Capital

Rose Capital is a strategic advisor and investment firm focused on the global medical and adult use legal cannabis sector.  It is funded by a small consortium of partners looking to access the industry through a diversified long-term, value-focused cannabis fund.  Rose Capital manages an ecosystem of best-in-class operating assets across the data, analytics & compliance, distribution & logistics, and consumer products & contract manufacturing verticals of the US cannabis market, expanding globally.  Please visit http://www.boldrosecapital.com.

About BioTrackTHC and Bio-Tech Medical Software, Inc.

Bio-Tech Medical Software, Inc., through its BioTrackTHC division, develops and provides effective cutting-edge technology solutions for the emerging medical and legal marijuana industry. Visit www.BioTrackTHC.com  for more information.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.  Actual results might differ materially from those explicit or implicit in the forward-looking statements.  Important factors that could cause actual results to differ materially include: our ability to fund our operations and pay any outstanding debt; fluctuations in our financial results; general economic risks; the volatile nature of the market for our products and services and other factors that could impact our anticipated growth; our ability to manage our growth; changes in laws and regulations regarding the cannabis industry and service providers in the cannabis industry; reliance on key personnel; our ability to compete effectively; security and other risks associated with our business; intellectual property risks; and other risk factors set forth from time to time in our SEC filings.  Helix TCS assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Helix TCS, Inc.